Gilead Sciences Inc. landed former Roche executive Daniel O'Day as its new CEO, and Genentech Inc.'s current CEO will take O'Day's role with Genentech's parent company in a game of musical chairs disclosed Sunday.
The job shuffling has implications up and down the employment ranks of the Bay Area's two largest drug makers during critical times for both companies. Gilead (NASDAQ: GILD), based in Foster City, is set up for deeper moves into next-generation cancer drugs while South San Francisco's…
